All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-05-21T08:31:35.000Z

Phase Ib final analysis — Isatuximab + carfilzomib

By Claire Baker
Featured
Nina Shah
May 21, 2020
Share:

Bookmark this article

During COMy 2020, Nina Shah, University of California, San Francisco, US, spoke to the Multiple Myeloma (MM) Hub about the phase Ib final analysis of isatuximab + carfilzomib.

The phase Ib study is evaluating the combination of isatuximab, an anti-CD38 monoclonal antibody, and carfilzomib, a proteasome inhibitor, for the treatment of relapsed or refractory MM. Results from this trial were previously presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which uncovered the promising safety and efficacy profiles of the regimen.

Phase Ib final analysis — Isatuximab + carfilzomib

More about...
CarfilzomibCOMyCOMy 2020IsatuximabRelapsed/refractory multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
26 votes - 7 days left ...

Related articles

Add bookmark

Is Isa+Kd efficacious in patients who have received prior ASCT?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne...

Mar 19, 2021
Add bookmark

Is Isa+Kd efficacious in patients who have received prior ASCT?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to...

Mar 19, 2021
Add bookmark

COMy 2020 | Highlights from the oral abstract session

A summary of the session entitled ‘Oral Abstracts’, which took place during the 6th World Congresses on Controversies in Multiple Myeloma (COMy) meeting, held virtually on Friday 15 May, 2020.

May 27, 2020
Add bookmark

COMy 2020 | Highlights from the oral abstract session

A summary of the session entitled ‘Oral Abstracts’, which took place during the 6th World Congresses on Controversies in Multiple Myeloma (COMy)...

May 27, 2020

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox